Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — Investor Presentation (March 2024)
20 slides from Captor Therapeutics Sa's investor presentation, Mar 11, 2024
Slide 1: Targeted Protein Degradation Q1 2024 Update
Targeted Protein Degradation Q1 2024 Update - DM Pekao - 1
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Advanced therapies from targeted protein degradation
Advanced therapies from targeted protein degradation Captor Therapeutics: Warsaw Exchange listed biotech (WSE: CTX): ~105 FTEs dedicated to targeted protein degradation (TPD) with facilities in Poland and Switzerland $2 billion innovation support program in Poland allows a capital sparing R&D model
Slide 4: Fully owned pipeline
Fully owned pipeline Program Primary Indications Modality Discovery Preclinical* IND Filing Phase IA / IB Phase II Target CT-01 GSPT1 Hepatocellular carcinoma, MG Lung cancer, NET tumors CT-02 NEK7 Autoimmunity, CNS, MG Metabolism, Oncology CT-03 MCL-1 Liquid & solid tumors BIFD CT-05 PKCӨ Autoimmun
Slide 5: An experienced leadership team
An experienced leadership team LEADERSHIP TEAM Tom Shepherd, Ph.D. Michal Walczak, Ph.D. Anna Pawluk, Ph.D. Sylvain Cottens, Ph.D. Chief Executive Officer Co-founder Head of Operations Co-founder Chief Scientific Officer SVP Chemistry • 30 years in Biotech • Ph.D. ETH Zurich, • Ph.D. University of W
Slide 6: New members of the leadership team
New members of the leadership team Andrew Saunders DPM, FFPM Donald Coppen, Ph.D. Tomas Drmota, Ph.D. Chief Medical Officer Business Development Director VP Early Discovery • MB BCh BAO BA, Medicine, Trinity • PhD, University of Southampton • PhD, Charles University Prague College Dublin • MBA, Cran
Slide 7: TPD: A new dawn in drug discovery
TPD: A new dawn in drug discovery Prolonged Different Outcomes Pharmaco-dynamics pharmacology Protein INHIBITION Small molecule inactivation time Inhibitors: • Frequent dosing • More side effects Disease-causing active protein inactive protein active protein protein Protein only inactive when bound
Slide 8: CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader
CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader Lung cancer GSPT1 degradation leads to an Integrated Stress Response 400k patients and induction of apoptosis in HCC cells SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis NEK7 deg
Slide 9: Liver cancer
Liver cancer Liver cancer • Fifth most common cancer • Second most frequent cause of cancer-related death globally • 905,000 new cases and 830,000 deaths per year • 7% of all cancers Hepatocellular Carcinoma (HCC) • Accounts for approximately 90% of primary liver cancers • Constitutes a major global
Slide 10: Epidemiology of Hepatocellular carcinoma
Epidemiology of Hepatocellular carcinoma USD 7.33 billion by 2027, with a CAGR of 17.39% Market estimates for systemic HCC therapies of $10.5-12.9B by 2030, with a CAGR of 15-20% 10
Slide 11: CT-01: Clinical trials in the short term
CT-01: Clinical trials in the short term In vitro and in vivo pharmacology and GLP-toxicology Drug substance for clinical trials Documentation for clinical trials Capsule preparation Underway CTA submission Scheduled for H1 First patient enrolled Autumn 2024 11
Slide 12: CT-02: Vast market potential for inflammasome modulators
CT-02: Vast market potential for inflammasome modulators Neuroinflammation NEK7 degradation inhibits the possibility of Allergy inflammasome formation and, consequently, the Asthma (AD, PD, MS, ALS) production of inflammatory cytokines leading to the reduction of symptoms of immune-related diseases
Slide 13: CT-02: Spectacular results for two different strategies
CT-02: Spectacular results for two different strategies Brain-penetrant lead Systemic lead compound compound Potent degradation of NEK7 in monkeys for 24h with single dose In vivo PoC in In vivo PoC in systemic model UNDERWAY neuroinflammation model Both compounds display excellent drug-like propert
Slide 14: CT-03: MCL-1 – a critical pathway of cancer resistance
CT-03: MCL-1 – a critical pathway of cancer resistance MCL-1 is one of the most amplified proteins in cancer A critical resistance mechanism in hematological and solid tumors Degradation of inhibition of MCL-1 protein directly attenuates tumors in vivo as monotherapy & sensitizes tumors for other th
Slide 15: MCL-1 as a target in numerous anticancer therapies
MCL-1 as a target in numerous anticancer therapies MCL-1 is a key mechanism of drug resistance in cancer cells Highly attractive target serving as a major survival signal in numerous cancers Hematological malignancies Multiple Myeloma (MM) Acute Myeloid Leukemia (AML) Non-Hodgkin Lymphoma (NHL) $33b
Slide 16: CT-03: Milestones
CT-03: Milestones MCL-1 degraders with very high potency in cancer models in vitro and in vivo Cardiosafety in vivo in monkeys by troponin level analysis Early toxicology Underway IND-enabling studies initiation H2 2024 IND approval 16
Slide 17: Steep rebound of XBI and other TPD companies in the last months
Steep rebound of XBI and other TPD companies in the last 6 months 17
Slide 18: Business opportunities beyond our pipeline
Business opportunities beyond our pipeline Degraders for new collaborative drug targets Similar to our partnership with Ono Pharmaceutical, this kind of collaboration can bring non-dilutive funding and build expertise in a new area Degraders working through novel ligases Novel ligases have the poten
Slide 19: Strong balance sheet and cash position
Strong balance sheet and cash position Consolidated statement of financial position (PLN, M) Cash position Available funding secured (PLN M; as of September 30, 2023): 101,3 96,3 Total : - PLN 114,3 M* PLN 54,3 cash, short-term bonds 63,5 54,3 114,3* 60,0 PLN 60,0 40,8 available grants (NCBR; ABM) 3
Slide 20: Captor Therapeutics S.A contact details
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Hegenheimermattweg 167A 4123 Allschwil, Switzerland Contact: relacje.inwestorskie@captortherapeutics.com 20
Captor Therapeutics — Investor Presentation (March 2024) on 6ix